
|Articles|May 1, 2007
Bevacizumab appears safe for neovascular AMD in short term
The short-term clinical experience with intravitreal bevacizumab (Avastin, Genentech) supports growing perception that treatment is safe and effective for neovascular age-related macular degeneration.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Opus Genetics launches phase 1/2 MERTK gene therapy trial
3
FDA approves NDA labeling supplement allowing re-administration of iDose TR
4
FDA Type C meeting supports phase 2b/3 pathway for urcosimod in neuropathic corneal pain
5



























